Andrew J. Wagner, John M. Goldberg, Steven G. DuBois, Edwin Choy, Lee Rosen, Alberto Pappo, James Geller, Ian Judson, David Hogg, Neil Senzer, Ian J. Davis, Feng Chai, Carol Waghorne, Brian Schwartz and George D. Demetri Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors Cancer 118
Article first published online: 17 MAY 2012 | DOI: 10.1002/cncr.27582
This multicenter, single-arm, 2-stage, phase 2 trial of the mesenchymal-epithelial transition factor inhibitor tivantinib (ARQ 197) enrolled patients with advanced microphthalmia transcription factor–associated (MiT) tumors. Tivantinib was safe and tolerable in patients with MiT tumors but had minimal single-agent antitumor activity.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field